Recent Externally Funded Research Awards

2017

3rd Quarter (July-September 2017)

BLAIN, PETER

• 2017 Summer 21st Century Scholars
  $19,612, US DEPT OF EDUCATION
• FY18 WIOA
  $39,662, US DEPT OF LABOR

DESABRAIS, MAUREEN

• FY18 Jail Health HIV Educator
  $53,022, HAMPDEN COUNTY SHERIFF'S DEPT
• Jail Health HIV Coordinator
  $42,829, HAMPDEN COUNTY SHERIFF'S DEPT

FRIEDMANN, MD PETER

• Drug Injection Surveillance and Care Enhancement for Rural Northern New England (DISCERNNE)
  $662,081, NAT INST ON DRUG ABUSE

HAESSLER MD, SARAH

• FY18 Ebola Predaredness
  $210,000, DEPT HEALTH AND HUMAN SERVICES

HERNANDEZ MONTFORT, MD JAMIE

• PARADISE-MI: Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction; A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the effic
  $184,244, NOVARTIS PHARMACEUTICALS CORP.

HOFFMAN, MD JAMES

• WIRB F. Hoffman-La Roche Ltd., YO39523 A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FAL
  $218,750, HOFFMAN-LA ROCHE, INC.

LINDENAUER, MD PETER

• A mixed methods study to analyze the use of pulmonary rehabilitation following hospitalization for COPD, and to identify effective strategies for increasing rates of participation
  $508,417 NAT. HEART LUNG BLOOD INST.

MADORE, MD LAURA

• Targeted fortification of human breast milk and its effects on body composition of preterm infants
  $98,536, RPAP

PACK, MD QUINN

• Identifying Effective Strategies to Improve Participation in Cardiac Rehabilitation after an Acute Cardiac Hospitalization
  $185,303, NAT. HEART LUNG BLOOD INST.

PEACOCK-CHAMBERS, LILI

• Implementation of a Reflective Functioning Intervention for Parents with Addiction Through Early Intervention Services
  $15,864, GDAP

ROGERS, ALLYSON

• VOCA Trauma - FY18
  $474,665, MA OFFICE OF VICTIM ASSISTANCE
• VOCA Homicide FY18
  $300,617, MA OFFICE OF VICTIM ASSISTANCE
• MACA FY18 - July 1, 2017 to June 30, 2018
  $25,000, NATIONAL CHILDREN'S ALLIANCE

ROMANELLI, MD JOHN

• Transgastric Inguinal Hernia Repair – a Cadaver Feasibility Study
  $34,000, AMERICAN SOC. GASTRO. ENDOSCOPY

SADOF, MD MATTHEW

• FY18 Masstart
  $30,000, DEPT HEALTH AND HUMAN SERVICES

SANKEY, MD HEATHER

• PRogram In Support of Moms (PRISM): Phase 2
  $10,855, UNIV OF MA MEDICAL SCHOOL

SARVET, MD BARRY

• MCPAP 2018 Medical Director Contract
  $69,752, BEACON HEALTH OPTIONS
• FY18 MCPAP for Moms
  $93,550, MA BEHAVIORAL HLTH PARTNERSHIP

SKIEST, MD DANIEL

• FY18 NEAETC
  $37,487, HRSA
• Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins: A Cardiac MRI Study
  $9,370, NAT. HEART LUNG BLOOD INST.
• Expanded Access IND Program to Provide Stamaril® Vaccine to Persons in the United States for Vaccination Against Yellow Fever
  $2,650, SANOFI US SERVICES INC.

VEHSE, MD NICO

• Participation in the Cystic Fibrosis Registry
  $56,370, CYSTIC FIBROSIS FOUNDATION

VISINTAINER, PAUL

• Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in Postural Tachycardia Syndrome
  $33,476, NAT. INSTITUTES OF HEALTH(NIH)

2nd Quarter (April-June 2017)

DANYEL ADAMS

• Patient Preferences Before and After Treatment for Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in the Emergency Room
  $11,500.00, Hartford Hospital

SARAH GOFF

• Additional Funding Project ACCCES
  $6,000.00, University of Massachusetts

JAMES HOFFMAN

• WIRB: AstraZeneca Pharmaceuticals LP D0816L00003 Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopi
  $59,800.00, Astra Zeneca

VICTOR PINTO-PLAYA

• INtervention Study In overweiGHT patients with COPD (INSIGHT COPD)
  $12,600.00, NIH

ALLYSON ROGERS

• NCA 2017
  $7,000.00, National Children's Alliance

1st Quarter (January-March 2017)

ADRZEJEWSKI, MD CHESTER

• Interdisciplinary education and clinical decision support to improve physician and nurse identification and reporting of transfusion associated circulatory overload (TACO)
  $3,000.00, Association of American Medical Colleges

ALLEN, MD HOLLEY

• A multicenter, Phase 3, randomized, open-label, active-controlled, parallel-group trial investigating the safety, tolerability, and efficacy of TransCon hGH administered once a week versus standard daily hGH replacement therapy over 52 weeks in prepuberta
  $62,804.00, ASCENDIS PHARMA A/S

DESCHAINE, NORMAN

• Ryan White Title C 2017
  $398,903.00, HEALTH RESOURCES & SVSC ADMIN
• 2017 Connecticut River Valley Farmworker Health Program COMMUNITY HEALTH CTRS
  $13,000.00, DEPT HEALTH AND HUMAN SERVICES

GHAOUI, MD RONY

• Novel Therapies in Alcoholic Hepatitis: Specimen Collection Study /Natural History St
  $11,824.00, BAYSTATE HEALTH, INC.

ISLAM, MD M. ASHEQUL

• Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System In Patients at Low Risk for Surgical Aortic Valve Replacement
  $180,924.00, MEDTRONIC, INC.

MADER, MD TIMOTHY

• Factors associated with outcome in elderly out-of-hospital cardiac arrest event survivors
  $30,000.00, LAERDAL FOUNDATION FOR ACUTE MEDICINE

MOORE, MD FRANKLIN

• Clinical Evaluation of the Sentosa SA HSV1/2 Qualitative PCR Test
  $15,000.00, Vela Research Singapore Pte Ltd

ROMAIN, SARAH

• Nursing Ethics Rounds Mass Humanities Grant
  $2,810.00, MASS HUMANITIES

SARVET, MD BARRY

• MCPAP 2017 Medical Director Contract
  $38,363.80, BEACON HEALTH OPTIONS

SCHOEN, MD CORINA

• TREETOP: Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor
  $217,600.00, SERA PROGNOSTICS, INC.

SINGH, MD RACHANA

• ELGAN 3: Environment, Epigenetics, Neurodevelopment & Health of Extremely Preterm Children
  $56,477.00, NAT. INSTITUTES OF HEALTH (NIH)
• Health Policy Commission, Health Care Innovation Investment Program for Neonatal Abstinence Syndrome Inpatient Care at Baystate
  $249,777.79, HEALTH POLICY COMMISSION COMMONWEALTH OF MASSACHUSETTS

STEINGRUB, MD JAY

• Vitamin D to Improve Outcomes by Leveraging Early Treatment
  $645,052.98, NAT. HEART LUNG BLOOD INST.

2016

4th Quarter (October-December 2016)

JERRY, JOSEPH

• ROH Breast Cancer Center Funding
  $240,000.00, BAYSTATE HEALTH, INC. RAYS OF HOPE 

JOHNSON, MD KARIN

• Novel Scoring Method for Obstructive Sleep Apnea
  $50,000.00, BAYSTATE HEALTH, INC. RPAP 

KAWAR, MD NADA

• BPA and Phthalates: Effects on Inflammatory Markers in the Breast and Breast Density in Young Women
  $68,095.00, NAT. INSTITUTES OF HEALTH (NIH) 

LINDENAUER, MD PETER

• Yale New Haven Health Services FY17 Core Measure
  $50,661.00, YALE NEW HAVEN HLTH SVCS CORP

MOORE, MD FRANKLIN

• De-identified Residual Sample Collection and Testing of the Investigational GI Panel on the GenMark ePlex Platform
  $13,500.00, GENMARK DIAGNOSTICS, INC. 

SCHMELKIN, MD IRA

• Multicenter, prospective, randomized study comparing the diagnostic yield of colon capsule endoscopy versus computed tomographic colonography in a screening population (TOPAZ” Study)
  $119,594.00, MEDTRONIC, INC. 

SCHNEIDER,PHD, SALLIE

• Identification and harmonization of intermediate endpoints for environmental exposures
  $60,075.00, NAT. INSTITUTES OF HEALTH(NIH)

SHENBERGER, MD JEFFREY

• NASCare: A mobile tool for diagnosis and treatment of neonatal abstinence syndrome
  $5,000.00, NAT INST ON DRUG ABUSE

SKIEST, MD DANIEL

• GEMINI 1 - A Phase III, randomised, double-blind, multicentre, parallel- group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected treatment-naïve adults
  $167,464.00, GLAXOSMITHKLINE

SUMMERS, MANDI

• FY17 Child Passenger Safety (CPS) Training and administration Grant
  $32,000.00, US DEPT OF HIGHWAY SAFETY

TIDSWELL, MD MARK

• Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936558 (nivolumab) in Participants with Severe Sepsis or Septic Shock
  $56,376.00, BRISTOL-MYERS SQUIBB
• Pilot study of non-invasive ventilatory support for acute hypoxemic respiratory failure: High flow nasal cannula vs. Helmet vs. Mask
  $49,997.00, BAYSTATE HEALTH, INC. RPAP

TIRABASSI, MD MICHAEL

• Evaluation of AntiGD2-PolyMPC−Dox Prodrugs in a Neuroblastoma Tumor Model
  $50,000.00, BAYSTATE HEALTH, INC. RPAP

TONYUSHKINA, KSENIA

• Engaging School Nurses in Diabetes Care Team to Improve Diabetes Self-management Skills, Adherence, and Glycemic Control in Children with T1DM.
  $49,991.00, BAYSTATE HEALTH, INC. RPAP

WASLICK, MD BRUCE

• Improving Patient-Centered Outcomes for Adolescents with Depressive Illness through the Massachusetts Child Psychiatry Access Project (MCPAP)
  $50,000.00, BAYSTATE HEALTH, INC. RPAP

WOZNIAK, JESSICA

• UMASS CTTC Training Grant, new SAMHSA Subaward
  $18,000.00, SUBST ABUSE MENTAL HLTH SVS AD

3rd Quarter (July-September 2016)

ANFANG, MD STUART

• Imaging Dementia - Evidence for Amyloid Scanning (IDEAS) Study: A Coverage with Evidence Development Longitudinal Cohort Study
  $67,500.00, AMERICAN COLLEGE OF RADIOLOGY

BLAIN, PETER

• 21st Century Scholars FY16 Summer Program
  $19,611.00, US DEPT OF EDUCATION
• FY17 WIOA
  45,000.00, US DEPT OF LABOR
• 21st Century Scholars School Year FY17
  $81,638.00, US DEPT OF EDUCATION

CONROY, MD RUSHIK

• A The Impact of Kurbo, a Pediatric Centered Weight Loss app, on BMI z Score Change in Obese Children and Adolescents
  $6,000.00, KURBO HEALTH INC

DESABRAIS, MAUREEN

• FY17 HIV Coordinator - Jail
  $42,629.00 HAMPDEN COUNTY SHERIFF'S DEPT
• FY17 HIV Educator - Jail
  $53,589.00, HAMPDEN COUNTY SHERIFF'S DEPT

DESCHAINE, NORMAN

• FY17 Medical Case Management
  $497,109.00, DEPT HEALTH AND HUMAN SERVICES
• FY17 PICSRT Budget 1
  $813,693.15, DEPT HEALTH AND HUMAN SERVICES
• FY17 ETI (PICSRT Budget 2)
  $65,000.00, DEPT HEALTH AND HUMAN SERVICES
• FY17 OBOT
  $105,779.00, DEPT HEALTH AND HUMAN SERVICES

FLACK, MD JOSEPH

• A Prospective, Multicenter, Non-Blinded, Non-Randomized Study of the Relay Pro thoracic Stent-Graft in Subjects with Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers
  $154,190.00, BOLTON MEDICAL INC.

HAESSLER MD, SARAH

• FY17 Ebola Preparedness
  $25,000.00, DEPT HEALTH AND HUMAN SERVICES

HEXDALL, MD AARON

• MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department (MERCURY PE)
  $17,760.00, JANSSEN PHARMACEUTICALS

LAGIER, CHRISTIAN

• TechSpring Community Builder
  $80,000.00, MASSACHUSETTS TECH COLLABORATIVE

LINDENAUER, MD PETER

• The Relationship Between Early Pulmonary Rehabilitation and Outcomes After Hospitalization for COPD
  $115,369.00, NAT. INSTITUTES OF HEALTH (NIH)

LOTFI, MD AMIR

• A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients with Multivessel Coronary Artery Disease: Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3
  $77,500.00, MEDTRONIC, INC.

MADER, MD TIMOTHY

• Evaluation of a simple tool for chest pain patient risk-stratification in North America
  $49,994.00, AGENCY HC RESEARCH & QUALITY

MOORE, MD FRANKLIN

• FilmArray Trend Research Project Study
  $5,000.00, BIOFIRE DIAGNOSTICS, LLC

OH, MD DENNIS

• A Randomised Controlled Study to Evaluate the Efficacy and Safety of Fibrin Sealant, Vapour Heated, Solvent/Detergent Treated (FS VH S/D 500 s apr) Compared to DuraSeal Dural Sealant as an Adjunct to Sutured Dural Repair in Cranial Surgery
  $145,688.00, BAXTER

PACHECO, JASON

• REB OJT Catalfamo
  $5,952.00, US DEPT OF LABOR

PAREDES, REBEKAH

• VOCA FY17 Trauma-focused
  $323,067.00, MA OFFICE OF VICTIM ASSISTANCE
• VOCA FY17 Homicide Bereavement
  $185,839.00, MA OFFICE OF VICTIM ASSISTANCE
• MACA FY17
  $25,000.00, MASS CHILDREN'S ALLIANCE

RATHLEV, MD NIELS

• Healing and preventing pain after injury: A randomized clinical trial of venlafaxine following motor vehicle collision
  $12,573.00, RHODE ISLAND HOSPITAL MAYDAY FOUNDATION

SADOF, MD MATTHEW

• FY17 Mass Start
  $28,000.00, DEPT HEALTH AND HUMAN SERVICES

SARVET, BARRY MD

• Partners in Care: Community-Based Implementation of Evidence-Based Treatment for Childhood Trauma
  $399,887.00, SUBST ABUSE MENTAL HLTH SVS AD
• MCPAP for Moms FY17
  $93,550.00, MA BEHAVIORAL HLTH PARTNERSHIP
• MCPAP FY17
  $550,000.00, MA BEHAVIORAL HLTH PARTNERSHIP

SKIEST, MD DANIEL

• FY17 NEAETC
  $35,100.00, HRSA

STEINGRUB, MD JAY

• A Randomized, Double-Blind, Placebo-Controlled, Four-Arm, Parallel-Group, Proof of Concept, and Dose-Finding Adaptive Phase 2a/2b Study to Investigate the Safety, Tolerability and Efficacy and Effect on Quality of Life of Human Recombinant Alkaline Phosph
  $76,328.00, AM PHARMA
• LOw Tidal volume Universal Support: Feasibility of RecrUitment for Interventional Trial
  $41,912.15, NAT. HEART LUNG BLOOD INST.

TIDSWELL, MD MARK

• A Phase 1b/2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Subjects with Severe Sepsis
  $118,996.00, BRISTOL-MYERS SQUIBB
• EUPHORIA Evaluating the Use of Polymyxin B Hemoperfusion in a Prospective Non-controlled Trial In Adults
  $254,834.00, SPECTRAL MEDICAL INC.

WYNNE, MONICA

• FY17 ASPR
  $26,687.08, DEPT HEALTH AND HUMAN SERVICES

2nd Quarter (April - June 2016)

BOOS, MD STEPHEN

• Project LAUNCH
  $69,969.00, SUBST ABUSE MENTAL HLTH SVS AD

CONROY, MD RUSHIKA

• The Impact of Kurbo, a Pediatric Centered Weight Loss app, on BMI z Score Change in Obese Children and Adolescents
  $6,000.00, KURBO HEALTH INC

LOTFI, MD AMIR

• A MULTI-CENTER EVALUATION OF THE DELIVERY OF INTRACORONARY HYPEROXEMIC SUPERSATURATED OXYGEN THERAPY FOR 60 MINUTES IN ANTERIOR ACUTE MYOCARDIAL INFARCTION PATIENTS WITH SUCCESSFUL REPERFUSION (VIA PCI) LESS THAN OR EQUAL TO SIX HOURS AFTER SYMPTOM ONSET
  $36,524.00, THEROX INC.

MCCANN, MD JOHN

• WIRB: BI 1200.209 A Single Arm Phase IV Study of Afatinib in Elderly Patients with recurrent or Stage IV Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have Common Epidermal Growth Factor Receptor (EGFR) mutations (Exon 19 Deletions or Exon 21 L858R Subs
  $45,000.00, BOEHRINGER INGELHEIM

MERTENS, MD WILSON

• WIRB: Galera Therapeutics, Inc. GT-201 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Trial of the Effects of Intravenous GC4419 on the Incidence and Duration of Severe Oral Mucositis (OM) in Patients Receiving Post-Operative or De
  $60,000.00, GALERA THERAPEUTICS, INC.

PACHECO, JASON

• REB OJT Catalfamo 5,952.00 REGION EMPL BOARD OF HAMDEN CTY US DEPT OF LABOR

PACHECO, JASON REB OJT March 2016 RN Group
$51,840.00, US DEPT OF LABOR

PAREDES, REBEKAH

• NCA 2016
  $9,000.00, NATIONAL CHILDREN'S ALLIANCE

QUIZON, MD ANNABELLE

• Participation in the Cystic Fibrosis Patient Registry
  $60,680.00, CYSTIC FIBROSIS FOUNDATION

SHENBERGER, MD JEFFREY

• A MULTICENTER, DOUBLE BLIND, RANDOMIZED, SINGLE DOSE, ACTIVE-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF SYNTHETIC SURFACTANT (CHF 5633) IN COMPARISON TO PORCINE SURFACTANT (PORACTANT ALFA, CUROSURF®) IN THE TREATMENT OF PRETERM NEONATES WI
  $89,964.00, CHIESI FARMACEUTICI S.P.A.

SINGH, MD RACHANA

• A Phase Ib/IIa Randomized, Placebo Controlled Study of the Safety and Efficacy of Once Daily Dosing of STP206 in Premature Very Low Birth Weight and Extremely Low Birth Weight Neonates
  $280,800.00, SIGMA-TAU PHARMACEUTICALS, INC.

SKIEST, MD DANIEL

• GS-US-380-1489: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
  $110,075.00, GILEAD SCIENCES, INC
• Cooperative Re-engagement Controlled Trial (CoRECT)
  $23,300.00, MA DEPT OF PUBLIC HEALTH (DPH)

1st Quarter (January - March 2016)

Iglesias Lino MD, Laura

• Practice Change Leaders
  $44,920, Univ Colorado Denver, The Atlantic Philanthropies

Deschaine, Norman

• 2016 Ryan White
  $425,326, Health Resources & Svsc Admin
• 2016 Migrant Farmworkers
  $7,810, Dept Health And Human Services

Friedmann, MD Peter

• Distress Tolerance And Hiv Prevention With Xr-Ntx Initiation In Opioid Dependence
  $5,881, Nat Inst On Drug Abuse

Nahmias, MD Jeffry

• A Phase Iv, Multicenter, Prospective, Randomized, Controlled Clinical Study To Compare The Irrisept System Versus Standard Of Care (Soc) On The Prevalence Of Surgical Site Infection (Ssi) In Patients With Abdominal Trauma Or Acute Surgical Abdomen
  $131,250, N/A

Ali, MD Syed

• Wirb: Tg Therapeutics, Inc. Utx-Ib-301 A Phase 3, Randomized, Study To Assess The Efficacy And Safety Of Ublituximab In Combination With Ibrutinib Compared To Ibrutinib Alone, In Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia
  $150,000, Tg Therapeutics, Inc.

Rousou, MD John

• A Randomized, Double-Blind, Placebo Controlled, Phase 2 Study To Evaluate The Efficacy And Safety Of Qpi-1002 For The Prevention Of Acute Kidney Injury In Subjects At High Risk For Aki Following Cardiac Surgery
  $160,720, Quark Pharmaceutical Inc.

Lee, MD Patrick

• A Health Economic Study Of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies To Investigate The Efficacy And Safety Of The Xaracoll® Bupivacaine Implant (300 Mg Bupivacaine Hydrochloride) After Open Laparotomy Hernioplasty
  $4,200, Innocoll Technologies, Ltd

Giugliano, MD Gregory

• Twilight Study: Ticagrelor With Aspirin Or Alone In High-Risk Patients After Coronary Intervention
  $112,500, Mt. Sinai School Of Medicine, Bayer Corporation

Makari-Judson, MD Grace

• Roh Crispr Editing Of Primary Breast Cells Tools For Precision Therapeutics And Diagnostics
  $25,000, Baystate Health, Rays Of Hope Ctr Br Ca Rsrch
• Roh Describing Eye Movement Changes Associated With Cancer-Related Fatigue Using Wearable Eye Technology $49,849, Baystate Health, Rays Of Hope Ctr Br Ca Rsrch
• Roh Anti-Parp1 Shrna-Delivering Bacteria To Treat Triple Negative Breast Cancer
  $25,000, Baystate Health, Rays Of Hope Ctr Br Ca Rsrch
• Roh Environmental Estrogens, Primary Breast Explants, And Dna Methylation Elucidating Mechanisms Of Individual Susceptibility
  $50,000, Baystate Health, Rays Of Hope Ctr Br Ca Rsch
• Roh Bpa Phthalates Effects On Breast Denisty In Young Women
  $25,000, Baystate Health, Rays Of Hope Ctr Br Ca Rsrch

Tidswell, MD Mark

• A Double-Blind, Randomised, Placebo-Controlled, Phase 2b/3 Adaptive Clinical Trial Investigating The Efficacy And Safety Of Selepressin As Treatment For Patients With Vasopressor-Dependent Septic Shock
  $85,854, Ferring Pharmaceuticals A/S

2015

4th Quarter (October - December 2015)

ENGELMAN, MD RICHARD

• CytoSorb® Reduction of Free Hemoglobin during Cardiac Surgery (REFRESH Trial)
  $35,305, CYTOSORBENTS INC.

FRIEDMANN, MD PETER

• Impact of health reform on outpatient substance abuse treatment programs
  $310,272, NIDA
• Implementation to motivate physician response to opiod dependence in HIV setting
  $868,936, NIDA
• Supplement: Implementation to motivate physician response to opiod dependence in HIV setting
  $150,000, NAT INST ON DRUG ABUSE

HAESSLER MD, SARAH

• Ebola Preparedness and Response Activities Grant FY16
  $25,000, DEPT HEALTH AND HUMAN SERVICES

HARMANLI, MD OZ

• A Post-Market Evaluation of the Altis Single Incision Sling System versus Transobturator or Retropubic Mesh Sling in the Treatment of Female Stress Urinary Incontinence (Altis 522 Study)
  $100,000, COLOPLAST CORP.

KATTAN, MD DAVID

• PostFellowship Family Planning Salary Support
  $53,880, ANONYMOUS FOUNDATION

LEE, MD PATRICK

• A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of the XaraColl® Bupivacaine Implant (300 mg Bupivacaine Hydrochloride) After Open Laparotomy Hernioplasty
  $138,840, INNOCOLL TECHNOLOGIES, LTD
• A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adult Subjects with Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
  $74,722,  PARATEK PHARMA LLC

MAKARI-JUDSON, MD GRACE

• M12-914 A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
  $309,000, ABBVIE, INC.

PACOCHA, DARLENE

• Aerogen Bench Study
  $15,000, AEROGEN LIMITED

ROUSOU, MD JOHN

• A Prospective, Randomized, Controlled Study to Evaluate the Effectiveness and Safety of CELSTAT as an Adjunct to Hemostasis for Tissue Bleeding in Cardiothoracic, General and Vascular Surgery
  $109,219, BAXTER

STEINGRUB, MD JAY

• Reevaluation of Systemic Early Neuromuscular Blockade (ROSE)
  $166,314, NAT.HEART LUNG BLOOD INST.

SUMMERS, MANDI

• Child Passenger Safety Training and Administration Program FY16
  $150,000, US DEPT OF HIGHWAY SAFETY